Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma

Türk, Murat; KOÇ, Ayşe Nedret; gökahmetoğlu, selma; Yilmaz, Insu

doi:10.55730/1300-0144.5418

Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma

Murat TÜRK, (Erciyes Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Allerji ve Klinik İmmünoloji Anabilim Dalı, Kayseri, Türkiye)

İnsu YILMAZ, (Erciyes Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Allerji ve Klinik İmmünoloji Anabilim Dalı, Kayseri, Türkiye)

Selma GÖKAHMETOĞLU, (Erciyes Üniversitesi, Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Kayseri, Türkiye)

Ayşe Nedret KOÇ (Erciyes Üniversitesi, Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Kayseri, Türkiye)

Turkish Journal of Medical Sciences

8 3

Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 1148 - 1159 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5418 İndeks Tarihi: 26-12-2022

Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma

Öz:

Background/aim: The differences in molecular mechanisms during a stable period and the changes in the inflammatory responses during exacerbations between distinct severe asthma phenotypes remain unclear. In this study, we aimed to characterize stable and exacerbation period serum cytokine and periostin levels of 5 different predefined severe asthma phenotypes with real-life data. Changes in the viral infection-induced exacerbations were also analyzed. Materials and methods: Serum levels of 8 cytokines and periostin were measured from the sera obtained from the adult patients with five different severe asthma phenotypes based on the presence/absence of aeroallergen sensitivity, peripheral eosinophilia and chronic rhinosinusitis with nasal polyposis (CRSwNP) during stable and exacerbation periods, and from the matched controls. Results: Serum IL-13, IL-25, TSLP, and periostin levels were similar between the patient and the control groups during stable and exacerbation periods. Serum IL-25 and TSLP levels, and peripheral eosinophil count and periostin level showed a strong correlation. Stable period periostin levels were significantly higher in eosinophilic patients, and eosinophilic patients without long-term systemic steroid therapy had higher IL-13 levels. Compared to stable period, exacerbation period serum periostin levels found significantly lower [5853 (2309–8427) pg/mL vs. 4479 (2766–6495) pg/mL; p = 0.05] and periostin levels were much lower in viral infection-induced exacerbations [2913 (893–4770) pg/mL vs. 7094 (4782–9596) pg/mL; p = 0.022]. Conclusion: Our study showed that serum periostin levels were decreased in viral infection-induced exacerbations and increased in the presence of eosinophilia independent from atopy and it can help to differentiate eosinophilia even if the patient is under long-term systemic steroid therapy. Also, serum IL-13 levels may reflect peripheral eosinophilia in patients without long-term systemic steroid use.

Anahtar Kelime: Severe asthma asthma phenotypes eosinophilic asthma allergic asthma nonallergic asthma type-2 high asthma

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal 2014; 43: 343-373. doi: 10.1183/13993003.52020-2013
2. Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA et al. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. Journal of Allergy and Clinical Immunology 2012; 129 (5): 1229-1235. doi: 10.1016/j.jaci.2012.01.039
3. Agache I. Severe asthma phenotypes and endotypes. Seminars in Immunoogyl 2019; 46: 101301. doi: 10.1016/j. smim.2019.101301
4. Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. American Journal of Respiratory and Critical Care Medicine 2010; 181 (4): 315-323. doi: 10.1164/rccm.200906-0896OC
5. Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. Journal of Allergy and Clinical Immunology 2019; 144 (1): 1-12. doi: 10.1016/j. jaci.2019.05.031
6. Yilmaz I, Terl M. Comment on: Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy. Allergy 2017; 72 (10): 1587-1589. doi: 10.1111/all.13188
7. Terl M, Sedlak V, Cap P, Dvorakova R, Kasak V et al. Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy. Allergy 2017; 72 (9): 1279-1287. doi: 10.1111/all.13165
8. Kuruvilla ME, Lee FE, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clinical Reviews in Allergy and Immunology 2019; 56 (2): 219- 233. doi: 10.1007/s12016-018-8712-1
9. Coverstone AM, Seibold MA, Peters MC. Diagnosis and Management of T2-High Asthma. Journal of Allergy and Clinical Immunology In Practice 2020; 8 (2): 442-450. doi: 10.1016/j.jaip.2019.11.020
10. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. American Journal of Respiratory and Critical Care Medicine 2009; 180 (5): 388-395. doi: 10.1164/ rccm.200903-0392OC
11. Yu S, Kim HY, Chang YJ, DeKruyff RH, Umetsu DT. Innate lymphoid cells and asthma. Journal of Allergy and Clinical Immunology 2014; 133 (4): 943-950. doi: 10.1016/j. jaci.2014.02.015
12. Chau-Etchepare F, Hoerger JL, Kuhn BT, Zeki AA, Haczku A et al. Viruses and non-allergen environmental triggers in asthma. Journal of Investigational Medicine 2019; 67 (7): 1029-1041. doi: 10.1136/jim-2019-001000
13. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. Journal of Allergy and Clinical Immunology 2003; 111 (4): 677-690. doi: 10.1067/mai.2003.1333
14. Emson C, Pham TH, Manetz S, Newbold P. Periostin and dipeptidyl peptidase-4: potential biomarkers of interleukin 13 pathway activation in asthma and allergy. Immunology and Allergy Clinics of North America 2018; 38 (4): 611-628. doi: 10.1016/j.iac.2018.06.004
15. Horie S, Okubo Y, Hossain M, Sato E, Nomura H et al. Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Internal Medicine 1997; 36 (3): 179-185. doi: 10.2169/internalmedicine.36.179
16. Hasegawa T, Uga H, Mori A, Kurata H. Increased serum IL-17A and Th2 cytokine levels in patients with severe uncontrolled asthma. European Cytokine Network 2017; 28 (1): 8-18. doi: 10.1684/ecn.2017.0390
17. Hussein YM, Alzahrani SS, Alharthi AA, Ghonaim MM, Alhazmi AS et al. Association of serum cytokines levels, interleukin 10 -1082G/A and interferon-gamma +874T/A polymorphisms with atopic asthma children from Saudi Arabia. Cellular Immunology 2014; 289 (1-2): 21-26. doi: 10.1016/j. cellimm.2014.03.006
18. Kalinauskaite-Zukauske V, Janulaityte I, Januskevicius A, Malakauskas K. Serum levels of epithelial-derived mediators and interleukin-4/interleukin-13 signaling after bronchial challenge with Dermatophagoides pteronyssinus in patients with allergic asthma. Scandinavian Journal of Immunology 2019; 90: e12820. doi: 10.1111/sji.12820
19. Lee YC, Lee KH, Lee HB, Rhee YK. Serum levels of interleukins (IL)-4, IL-5, IL-13, and interferon-gamma in acute asthma. Journal of Asthma 2001; 38 (8): 665-671. doi: 10.1081/jas- 100107544
20. Agache I, Strasser DS, Pierlot GM, Farine H, Izuhara K et al. Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma. Journal of Allergy and Clinical Immunology 2018; 141 (1): 442- 445. doi: 10.1016/j.jaci.2017.08.027
21. Agache I, Strasser DS, Klenk A, Agache C, Farine H et al. Serum IL-5 and IL-13 consistently serve as the best predictors for the blood eosinophilia phenotype in adult asthmatics. Allergy 2016; 71 (8): 1192-1202. doi: 10.1111/all.12906
22. Nabavi M, Arshi S, Bahrami A, Aryan Z, Bemanian MH et al. Increased level of interleukin-13, but not interleukin-4 and interferon-gamma in chronic rhinosinusitis with nasal polyps. Allergologia et Immunopathologia 2014; 42 (5): 465-471. doi: 10.1016/j.aller.2013.06.007
23. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases. Journal of Allergy and Clinical Immunology 2016; 138 (4): 984-1010. doi: 10.1016/j.jaci.2016.06.033
24. James A, Janson C, Malinovschi A, Holweg C, Alving K et al. Serum periostin relates to type-2 inflammation and lung function in asthma: Data from the large population-based cohort Swedish GA(2)LEN. Allergy 2017; 72 (11): 1753-1760. doi: 10.1111/all.13181
25. Mogensen I, James A, Malinovschi A. Systemic and breath biomarkers for asthma: an update. Current Opinion in Allergy and Clinical Immunology 2020; 20: 71-79. doi: 10.1097/ ACI.0000000000000599
26. Kurowski M, Jurczyk J, Jarzebska M, Wardzynska A, Krysztofiak H et al. Serum but not exhaled breath condensate periostin level is increased in competitive athletes. Clinical Respiratory Journal 2018; 12 (5): 1919-1926. doi: 10.1111/crj.12759
27. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. Journal of Allergy and Clinical Immunology 2012; 130 (3): 647-654. doi: 10.1016/j.jaci.2012.06.025
28. Asano T, Kanemitsu Y, Takemura M, Yokota M, Fukumitsu K et al. Serum periostin as a biomarker for comorbid chronic rhinosinusitis in patients with asthma. Annals of the American Thoracic Society 2017; 14 (5): 667-675. doi: 10.1513/ AnnalsATS.201609-720OC
29. Semprini R, Shortt N, Ebmeier S, Semprini A, Varughese R et al. Change in biomarkers of type-2 inflammation following severe exacerbations of asthma. Thorax 2019; 74 (1): 95-98. doi: 10.1136/thoraxjnl-2018-211657
30. Gern JE. Virus/allergen interaction in asthma exacerbation. Annals of the American Thoracic Society 2015; 12: 137-143. doi: 10.1513/AnnalsATS.201503-153AW
31. Gill MA, Bajwa G, George TA, Dong CC, Dougherty, II et al. Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. Journal of Immunology 2010; 184 (11): 5999-6006. doi: 10.4049/jimmunol.0901194
32. Pritchard AL, Carroll ML, Burel JG, White OJ, Phipps S et al. Innate IFNs and plasmacytoid dendritic cells constrain Th2 cytokine responses to rhinovirus: a regulatory mechanism with relevance to asthma. Journal of Immunology 2012; 188 (12): 5898-5905. doi: 10.4049/jimmunol.1103507
33. Schandene L, Del Prete GF, Cogan E, Stordeur P, Crusiaux A et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. Journal of Clinical Investigation 1996; 97 (2): 309-315. doi: 10.1172/ JCI118417
34. Huber JP, Ramos HJ, Gill MA, Farrar JD. Cutting edge: Type I IFN reverses human Th2 commitment and stability by suppressing GATA3. Journal of Immunology 2010; 185 (2): 813-817. doi: 10.4049/jimmunol.1000469

APA	Türk M, Yilmaz I, gökahmetoğlu s, KOÇ A (2022). Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma. , 1148 - 1159. 10.55730/1300-0144.5418
Chicago	Türk Murat,Yilmaz Insu,gökahmetoğlu selma,KOÇ Ayşe Nedret Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma. (2022): 1148 - 1159. 10.55730/1300-0144.5418
MLA	Türk Murat,Yilmaz Insu,gökahmetoğlu selma,KOÇ Ayşe Nedret Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma. , 2022, ss.1148 - 1159. 10.55730/1300-0144.5418
AMA	Türk M,Yilmaz I,gökahmetoğlu s,KOÇ A Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma. . 2022; 1148 - 1159. 10.55730/1300-0144.5418
Vancouver	Türk M,Yilmaz I,gökahmetoğlu s,KOÇ A Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma. . 2022; 1148 - 1159. 10.55730/1300-0144.5418
IEEE	Türk M,Yilmaz I,gökahmetoğlu s,KOÇ A "Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma." , ss.1148 - 1159, 2022. 10.55730/1300-0144.5418
ISNAD	Türk, Murat vd. "Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma". (2022), 1148-1159. https://doi.org/10.55730/1300-0144.5418

APA	Türk M, Yilmaz I, gökahmetoğlu s, KOÇ A (2022). Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma. Turkish Journal of Medical Sciences, 52(4), 1148 - 1159. 10.55730/1300-0144.5418
Chicago	Türk Murat,Yilmaz Insu,gökahmetoğlu selma,KOÇ Ayşe Nedret Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma. Turkish Journal of Medical Sciences 52, no.4 (2022): 1148 - 1159. 10.55730/1300-0144.5418
MLA	Türk Murat,Yilmaz Insu,gökahmetoğlu selma,KOÇ Ayşe Nedret Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.1148 - 1159. 10.55730/1300-0144.5418
AMA	Türk M,Yilmaz I,gökahmetoğlu s,KOÇ A Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma. Turkish Journal of Medical Sciences. 2022; 52(4): 1148 - 1159. 10.55730/1300-0144.5418
Vancouver	Türk M,Yilmaz I,gökahmetoğlu s,KOÇ A Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma. Turkish Journal of Medical Sciences. 2022; 52(4): 1148 - 1159. 10.55730/1300-0144.5418
IEEE	Türk M,Yilmaz I,gökahmetoğlu s,KOÇ A "Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma." Turkish Journal of Medical Sciences, 52, ss.1148 - 1159, 2022. 10.55730/1300-0144.5418
ISNAD	Türk, Murat vd. "Stable and exacerbation period serum cytokine and periostin levels of the five distinct phenotypes of severe asthma". Turkish Journal of Medical Sciences 52/4 (2022), 1148-1159. https://doi.org/10.55730/1300-0144.5418